DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Postoperative Acute Pain Market Insights, Epidemiology, and Market Forecast–2036.” This comprehensive report provides an in-depth understanding of Postoperative Acute Pain, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Postoperative Acute Pain Market

• The market size for Postoperative Acute Pain in the leading markets is expected to grow significantly by 2036.

• As per DelveInsight’s estimates, the total market size of Postoperative Acute Pain was nearly USD 1,200 million in the 7MM in 2025.

• The United States accounted for the highest Postoperative Acute Pain treatment market size among the 7MM in 2025 compared with the EU4 countries, the United Kingdom, and Japan.

• Among EU4 and the UK, Germany had the largest market size for Postoperative Acute Pain in 2025.

• The total number of incident cases of Postoperative Acute Pain in the 7MM were around 89.9 million in 2025.

• The United States reported approximately 45 million incident cases of Postoperative Acute Pain in 2025, with cases anticipated to increase during the forecast period.

• In 2025, approximately 14% of the incident cases of Postoperative Acute Pain were reported in Germany.

• According to a nationwide observational cohort study by Dobbs et al. (2021), a total of 3,102,674 surgical procedures were performed in England and Wales in 2020 compared to a predicted 4,671,338 procedures.

• In 2025, Japan reported approximately 20%, 15%, and 10% cases of mild, moderate, and severe postoperative acute pain, respectively, out of the 7MM.

• Leading Postoperative Acute Pain companies such as Vertex Pharmaceuticals, Tris Pharma, Cali Biosciences, Viatris, Allay Therapeutics, Latigo Biotherapeutics, Concentric Analgesics, Xgene Pharmaceutical, and others are developing novel therapies to improve pain management.

• The promising Postoperative Acute Pain therapies in development include Cebranopadol (TRN-228), CPL-01, MR-107A-02, LTG-001, ATX101, XG005, TLC590, Vocacapsaicin (CA-008), and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/post-operative-acute-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Postoperative Acute Pain Market

• Increasing Number of Surgical Procedures: Rising surgical volumes globally, including inpatient and outpatient procedures, are significantly contributing to the growing burden of postoperative acute pain and demand for effective analgesic therapies.

• Growing Adoption of Multimodal Analgesia: Current treatment strategies increasingly emphasize multimodal analgesia approaches combining opioids, NSAIDs, local anesthetics, and adjunctive therapies to improve pain relief while minimizing opioid-related risks and adverse events.

• Rising Demand for Non-opioid Therapies: Concerns regarding opioid dependence, misuse, and associated side effects are accelerating the demand for safer, long-acting, and opioid-sparing treatment alternatives.

• Advancements in Long-acting and Novel Pain Therapies: The emergence of therapies such as ZYNRELEF, EXPAREL, JOURNAVX, and innovative pipeline agents targeting novel pain pathways is expected to reshape postoperative pain management practices.

Postoperative Acute Pain Competitive Landscape

• Several Postoperative Acute Pain therapies in development include Cebranopadol (TRN-228) (Tris Pharma), CPL-01 (Cali Biosciences), MR-107A-02 (Viatris), LTG-001 (Latigo Biotherapeutics), ATX101 (Allay Therapeutics), CA-008 (Concentric Analgesics), XG005 (Xgene Pharmaceutical), and others.

• These therapies target multiple pain pathways and mechanisms, including dual NOP/MOP receptor agonism, selective Nav1.8 inhibition, long-acting local anesthetic delivery, and TRPV1 receptor modulation, aiming to provide improved efficacy with reduced opioid exposure and enhanced postoperative recovery outcomes.

Discover more about therapies set to grab major Postoperative Acute Pain market share @ Postoperative Acute Pain Treatment Landscape

Recent Developments in the Postoperative Acute Pain Market

• In March 2026, Vertex Pharmaceuticals presented new clinical data on JOURNAVX (suzetrigine) demonstrating effective pain management in postoperative acute pain patients.

• In April 2026, Tris Pharma announced multiple presentations related to cebranopadol during the 51st Annual Regional Anesthesiology and Acute Pain Medicine Meeting (ASRA).

• In March 2026, Tris Pharma presented Phase III ALLEVIATE-1 and ALLEVIATE-2 study data evaluating cebranopadol in patients following abdominoplasty and bunionectomy surgery at the American Academy of Pain Medicine (AAPM) 2026 Pain Connect annual meeting.

• In March 2026, Viatris announced that it anticipates a regulatory decision in the second half of 2026 for MR-107A-02, its fast-acting meloxicam therapy for acute pain.

• In June 2025, funds were secured to advance the Phase IIb registrational trial of ATX101 in post-surgical pain following total knee replacement.

• In March 2025, the US FDA granted Fast Track Designation to LTG-001, Latigo Biotherapeutics’ investigational selective Nav1.8 inhibitor for the treatment of acute pain.

What is Postoperative Acute Pain?

Postoperative acute pain is an acute condition experienced by patients following surgical procedures and represents one of the most common complications associated with surgery. Effective pain management is essential to improve recovery, reduce complications, enhance patient outcomes, and shorten hospital stays.

Postoperative pain management involves both pharmacological and non-pharmacological approaches. Current pharmacological options include opioids, NSAIDs, acetaminophen, local anesthetics, corticosteroids, gabapentinoids, alpha-2 agonists, and combination therapies. Non-pharmacological interventions include acupuncture, physical therapy, meditation, cognitive-behavioral approaches, and Transcutaneous Electrical Nerve Stimulation (TENS).

The current treatment paradigm increasingly emphasizes multimodal analgesia strategies that combine therapies with different mechanisms of action to optimize efficacy and reduce opioid-related adverse effects and dependency risks.

Postoperative Acute Pain Epidemiology Segmentation

The Postoperative Acute Pain epidemiology section provides insights into the historical and current patient pool and forecasted trends for the leading markets. The Postoperative Acute Pain market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Incident Cases of Postoperative Acute Pain

• Severity-specific Incident Cases of Postoperative Acute Pain

• Total Treated Cases of Postoperative Acute Pain

• Country-specific Incident Cases of Postoperative Acute Pain

Scope of the Postoperative Acute Pain Market Report

• Therapeutic Assessment: Postoperative Acute Pain current marketed and emerging therapies

• Postoperative Acute Pain Market Dynamics: Key Market Forecast Assumptions of Emerging Postoperative Acute Pain Drugs and Market Outlook

• Key Companies: Vertex Pharmaceuticals, Tris Pharma, Cali Biosciences, Viatris, Allay Therapeutics, Latigo Biotherapeutics, Concentric Analgesics, Xgene Pharmaceutical, and others

• Key Therapies: JOURNAVX (suzetrigine), ZYNRELEF (HTX-011), EXPAREL, Cebranopadol (TRN-228), CPL-01, MR-107A-02, LTG-001, ATX101, TLC590, and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Postoperative Acute Pain Market Access and Reimbursement

To know more about Postoperative Acute Pain companies working in the treatment market, visit @ Postoperative Acute Pain Clinical Trials and Therapeutic Assessment

Table of Contents

1. Postoperative Acute Pain Market Report Introduction

2. Executive Summary for Postoperative Acute Pain

3. SWOT Analysis of Postoperative Acute Pain

4. Postoperative Acute Pain Patient Share (%) Overview at a Glance

5. Postoperative Acute Pain Market Overview at a Glance

6. Postoperative Acute Pain Background and Overview

7. Postoperative Acute Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Postoperative Acute Pain

9. Postoperative Acute Pain Current Treatment and Medical Practices

10. Postoperative Acute Pain Unmet Needs

11. Postoperative Acute Pain Emerging Therapies

12. Postoperative Acute Pain Market Outlook

13. Country-Wise Postoperative Acute Pain Market Analysis (2022–2036)

14. Postoperative Acute Pain Market Access and Reimbursement of Therapies

15. Postoperative Acute Pain Market Drivers

16. Postoperative Acute Pain Market Barriers

17. Postoperative Acute Pain Appendix

18. Postoperative Acute Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services